NGS - COST Action BM1006: Next Generation Sequencing Data Analysis Network
From 17-01-2011 to 17-03-2015
Description
Next generation sequencing (NGS) is a highly parallelised approach for quickly and economically sequencing new genomes, re-sequencing large numbers of known genomes, or for rapidly investigating transcriptomes under different conditions. Producing data on an unprecedented scale, these techniques are now driving the generation of knowledge (especially in biomedicine and molecular life sciences) to new dimensions. The massive data volumes being generated by these new technologies require new data handling and storage methods. Hence, the life science community urgently needs new, and improved approaches to facilitate NGS data management and analysis. This COST Action unites bioinformaticians, computer scientists and biomedical scientists, harnessing their expertise to bring NGS data management and analysis to new levels of efficiency and integration. Rigorous surveillance of NGS technology and NGS-related software developments will allow the partners to generate software solutions for future NGS opportunities in a timely manner. The Action will increase the ability of European groups to maximally benefit from NGS technology, and will create a nucleus for world-wide activities to jointly address the upcoming biomedical informatics revolution.Team
- Jan Aerts, Team member
Financing
Funding: EU Funding - European Funding
Program/Grant Type: EU COST - European Cooperation in Science and Technology
Events
2/09/2024:
PhD defense - Martijn Oldenhof
Machine Learning for Advanced Chemical Analysis and Structure Recognition in Drug Discovery
3/09/2024:
Meet the Jury Igor Tetko on Advanced Machine Learning in Drug Discovery
12/09/2024:
Multimodal analysis of cell-free DNA for sensitive cancer detection in low-coverage and low-sample settings
Seminar by Antoine Passemiers
News
STADIUS Alumni Herman Verrelst – new CEO of Biocartis
08 June 2017
Herman Verrelst, the founder of KU Leuven spin-off Cartagenia, who has been working in Silicon Valley, US for the last few years will be returning to Belgium to follow the steps of Rudi Pauwels as CEO of the Belgian diagnostic company, Biocartis.
Supporting healthcare policymaking via machine learning – batteries included!
29 May 2017
STADIUS takes the lead in the data analytics efforts in an ambitious European Project MIDAS.
Marc Claesen gives an interview about his PhD for the magazine of the Faculty of Engineering Sciences "Geniaal"
10 February 2017
Did you know that in Belgium approximately one third of type 2 diabetes patients are unaware of their condition?
Joos Vandewalle is nieuwe voorzitter KVAB
09 October 2016
Op 5 oktober 2016 heeft de Algemene Vergadering van de Academie KVAB Joos Vandewalle verkozen tot voorzitter van de KVAB.